Objectives: The objective of this study was to identify specific histopathological features of skeletal muscle involvement in systemic sclerosis (SSc) patients.
Introduction
Systemic sclerosis (scleroderma, SSc) is an autoimmune connective tissue disease characterized by skin and internal organ fibrosis, coupled with widespread vascular pathology [Korn, 2001] . Skeletal muscle involvement in SSc was first considered in 1876, as a minor component of the disease associated with disuse [Medsger et al. 1968] .
Nowadays, SSc skeletal muscle involvement turns out to be a common feature, with prevalence from 14% to 79% [Paik et al. 2014 ]. This variable prevalence results from the heterogeneous criteria used to define muscle involvement in SSc, including clinical, biological, electromyographic (EMG) and histological features of muscle weakness [Olsen et al. 1996 ]. In fact, SSc myopathy can occur for different reasons, such as result of nonautoimmune etiologies: malnutrition, disuse, or other neuromuscular disorders [Clements et al. 1978] . Another important issue related to defining specific criteria for recognizing 'SSc myopathy' as such an entity, is the exclusion (or not) of SSc overlap syndromes, since inflammatory myopathies such as polymyositis (PM) or dermatomyositis (DM) are a common feature in these syndromes [Pope, 2002] . Despite the absence of definite criteria for the diagnosis of 'SSc myopathy', researchers agree on the fact that SSc-muscle involvement is a negative prognostic feature impacting survival, and has also been associated with cardiopulmonary complications and even sudden cardiac death [Follansbee et al. 1993] . For these reasons, in the present study we tried to identify histopathological hallmarks of 'SSc myopathy' that could be unique for the disease itself and not common to other idiopathic inflammatory myopathies (IIM) or to other noninflammatory myopathies (NIM).
Methods

Patients and diagnostic procedures
We admitted 112 SSc patients in our institution from 2010 to 2015. Patients who had been diagnosed according to the 2013 American College of Rheumatology and European League Against Rheumatism (ACR/EULAR) diagnostic criteria for SSc [Van Den Hoogen, 2013] , were enrolled. In total, 35 out of the 112 (32%, including 81% female and 68% diffuse scleroderma) who presented clinical, biological and EMG features of muscle involvement, were enrolled. Table 1 shows the main clinical and biological features of enrolled patients. Patients underwent biopsy of the vastus lateralis muscle. Specimens were frozen in liquid nitrogen-cooled isopentane and stored at −80°C until use. Cryostat sections were submitted to diagnostic routine histological and histochemical stains. SSc muscle biopsies were compared with (n = 35, site-matched) biopsies of patients with IIM, diagnosed following current clinicopathological criteria [Dalakas, 2010] [(n = 15 PM; n = 10 DM; n = 10 inclusion body myositis (IBM)], and to (n = 35, site-matched) biopsies of patients with NIM (n = 21 (A) metabolic myopathies, n = 14 (B) congenital myopathies): (A) n = 5 aspecific myopathic changes at biopsy; n = 4 statin associated rhabdomyolysis; n = 4 mitochondrial myopathy; n = 3 muscle glycogenosis; n = 5 steroid myopathy. (B) n = 2 calpainopathy; n = 3 mild dystrophinopathy; n = 2 myotonic dystrophy type 1; n = 2 myotonic dystrophy type 2; n = 2 facioscapulohumeral dystrophy; n = 3 oligosymptomatic familial hyperckemia). All subjects signed an informed consent, with allowance for scientific utilization of muscle samples for research purposes, in accordance to the principles of the 1975 Declaration of Helsinki (revised Hong Kong 1989) and the entire study protocol was approved by the institutional review board of the Ethics Committee of the University of Siena.
Histology and histoenzymatic stains
Cryostat 10 µm thick sections were submitted to routine hematoxylin-eosin and modified Gomori trichrome for morphological evaluation. Histoenzymatic stains for nicotinamide adenine dinucleotide (NADH) tetrazolium reductase, succinic dehydrogenase, cytochrome c oxidase, Periodic Acid Schiff (PAS) were also carried out.
Immunohistochemistry
Immunohistology for diagnostic routine analysis [CD4, CD8, CD20, human leucocyte antigens ABC (HLA-ABC), membranolytic attack complex (MAC)] (Dako, Glostrup, Denmark) was carried out on 7 µm thick cryostat sections on silane-coated slides (StarFrost; Knittel Gläser, Braunschweig, Germany). Vascular involvement was assessed by endothelial marker [cluster of differentiation 31 (CD31)] (Dako), pro-angiogenic vascular endothelial growth factor A (VEGF-A) (abcam, Cambridge, UK) and antiangiogenic VEGF-A 165b (abcam). Muscle fibrosis was assessed by the analysis of type I collagen (Coll-I) (abcam) and transforming growth factor β (TGF-β) (abcam). All the reactions were performed by immunoperoxidase technique, by horseradish peroxidase (HRP)-labeled polymer (Dako), and 3,3'-diaminobenzidine (Sigma-Aldrich, Milan, Italy) for visualization. Negative controls were performed by the omission of the primary antibody.
Transmission electron microscopy analysis
Ultrastructural analysis of SSc muscle specimens was performed routinely after fixation in 2.5% glutaraldehyde for 3 h at 4°C, post fixation in 1% osmium tetroxide, and embedding in araldite. Ultrathin sections were stained with uranyl acetate and lead citrate and were observed at Philips EM-10 electron microscope (Huntsville, Alabama, USA).
Quantitative analysis on immunohistochemical slides
Morphometry was carried out by a Zeiss AxioPlan2 microscope equipped with AxioVision 4.6 software (Carl Zeiss Vision GmbH, Hallbergmoos, Germany). Microangiopathy (CD31 + endomysial vessels, VEGF-A and VEGF-A 165b ), inflammation (deposits of CD4, CD8, CD20 reactive cells), major histocompatibility complex (MHC)-I complex fibral neoexpression HLA-ABC, complement deposition MAC and fibrosis (Coll-I, TGF-β) were evaluated as histopathological parameters of muscle involvement. The density of CD31 + endomysial vessels was expressed as a capillary to fiber ratio of muscle area, by counting vessels on the whole sections immunostained for CD31. VEGF analysis consisted of VEGF-A 165b /VEGF-A ratio of consecutive sections. Inflammatory (CD20, CD4, CD8), fibrotic (Coll-I, TGF-β) and complement deposition MAC scores were assessed on three randomly selected fields at 100× magnification by automatized colorimetric pixel evaluation, detecting the peroxidase reaction product. Each score was expressed as the marker + percentage of the total area.
Statistical analysis
Data were evaluated by GraphPad Prism 6 ® software for Windows. Analysis of variance (ANOVA) was performed by Kruskal-Wallis test for multiple groups. Significance was set at p < 0.05. Data are expressed as means ± standard deviations (SD).
Results
Histopathology
General myopathic changes, such as increased variability of fiber diameter, scattered atrophic fibers and occurrence of internalized nuclei were At the time of muscle biopsy (years) 4.5 ± 3.7 4.9 ± 3.7
ANA titer ⩾ 1:160 Pharmacological treatment: SSc patients enrolled in the study were in treatment with Iloprost (11 lSSc and 24 dSSc) for secondary Raynaud's phenomenon, with dual endothelin-1 receptor antagonist Macitentan (4 lSSc and 16 dSSc) for pulmonary arterial hypertension (PAH), with dual endothelin-1 receptor antagonist Bosentan (2 lSSc and 4 dSSc) for digital ulcers, with prokinetic and proton pump inhibitor agents (1 lSSc and 2 dSSc). It is important to underline that all the SSc patients enrolled in the study stopped treatments with low dose corticosteroids (<4-8 mg/die) and with immunosuppressive drugs at least three months before muscle biopsy.
detected. Multifocal endomysial fibrosis and scattered dilated endomysial capillaries were also observed. Necrosis/regeneration was not prominent, with occasional single fiber necrosis in a minority of subjects.
Immunohistology and quantitative analysis
Immunohistology for diagnostic routine analysis (CD4, CD8, CD20, Figure 1 ; HLA-ABC, MAC, Figure 2 ) were reported with the relative quantitative analysis. The inflammatory cells result was present only in IIM group. Limited or no reactivity was recorded in NIM (p < 0.001) and SSc (p < 0.001) groups, while the sarcolemmal/cytoplasmic stain of HLA-ABC and MAC deposition on endomysial capillaries is statistically higher in SSc myopathy (p < 0.01; p < 0.05) and IIM (p < 0.01; p < 0.01) groups compared with the NIM group. Moreover, HLA-ABC and MAC stainings in the SSc myopathy group seem to be comparable to those of IIM group. In Figure 3 , vascular involvement, represented by VEGF-A, VEGF-A 165b , CD31 and fibrotic component (represented by Coll-I and TGF-β) are reported. The VEGF-A 165b :VEGF-A ratio is statistically higher in SSc myopathy (p < 0.01) and IIM (p < 0.05) groups compared with the NIM group. The density of CD31 + endomysial vessels is statistically decreased in the SSc myopathy group compared with the IIM (p < 0.05) and NIM (p < 0.01) groups. In addition, Coll-I and TGF-β reveal strong expression in activated endomysial and perimysial myofibroblasts of the SSc myopathy group, and also in the fibroblasts and in some inflammatory cells surrounding the necrotic fibers in the IIM group. Faint Coll-I and TGF-β immunoreactivity is recorded in the resident endomysial and perimysial fibroblasts of the NIM group. Quantitative analysis shows that Coll-I and TGF-β are statistically higher in the SScmyopathy group compared with the IIM (p < 0.05; p < 0.01) and NIM (p < 0.01; p < 0.01) groups. Figure 4 shows a transmission-electron-microscopy (TEM) analysis of SSc muscle biopsies. Thickening and lamination of the basement membrane (middle), coupled to endothelial cell 'swelling' (left) are the main hallmark of SSc microangiopathy. Moreover, considerable endomysial fibrosis (right) with a large deposition of collagen is also observed.
TEM analysis
Discussion
The most important problem when analyzing the literature of SSc-related muscle involvement is the total absence of specific criteria for the diagnosis of such an entity [Ranque et al. 2007 ]. This is because clinical, biological, EMG and histopathological features are very heterogeneous, and also because SSc-associated myopathy often includes several distinct entities with different pathogenetic mechanisms involved, and with distinct outcomes [Ranque et al. 2007; Morrisroe et al. 2015] . Even when focusing on muscle histopathological findings only, no clear-cut classification has emerged [Paik et al. 2015] . Therefore, novel insights on the immunopathological nature of SSc muscle involvement are needed. For this reason, in this study we tried to identify histopathological hallmarks that could be specific for SSc myopathy and not common to other IIM and NIM. Whether the association of IIM and SSc constitutes an overlap syndrome or should be considered a SSc manifestation still remains controversial [Troyanov et al. 2005; Bhansing et al. 2014] . We demonstrated that fibrosis (81%) and microangiopathy (92%) are the main histopathologic hallmarks of SSc-related myopathy. We evidenced a reduced vascularization of muscle fibers through the analysis of CD31, and the prevalence of anti-angiogenic isoform VEGF-A 165b , as confirmed by other researchers, finding increased VEGF-A 165b plasmatic levels in SSc patients [Manetti et al. 2013 ]. However, these vascular alterations are not specific to SSc; they could be present also in other IIM myopathies, such as PM and DM, as has been well described in the literature [Volpi et al. 2013] . Regarding the inflammatory infiltrate, our study detected an absence of inflammatory cells in the majority of SSc cases (85%). MAC capillary deposits, compatible with a humoral immune process, suggest that endothelial injury and intimal proliferation may be mediated by complement-fixing antibodies [Evans et al. 1987] . Loss in muscle small endomysial vessels in SSc myopathy indicates a vasculopathy, with proliferative changes of the vessels wall, as evidenced by ultrastructural examination, as an early step in tissue damage, in analogy with skin and internal organs [Asano and Sato, 2015] . Nevertheless, HLA-ABC upregulation is considered an immunohistologic hallmark of inflammatory myopathies [Dalakas, 2010] .
In view of our consistent finding of MHC-I fibral staining on SSc myopathy, with no relevant infiltrates or myonecrosis, a role of pleiotropic TGF-β might be speculated about as a negative IIM, idiopathic inflammatory myopathies; NIM, noninflammatory myopathies; SSc, systemic sclerosis; TGF-β-A, transforming growth factor β-A; VEGF-A, pro-angiogenic vascular endothelial growth factor A; VEGF-A 165b , anti-angiogenic vascular endothelial growth factor A.
modulator of cell immunity [Morikawa et al. 2016] , in reducing the extent of muscle inflammation, at least in the early phases of muscle involvement, and acting as a pro-fibrotic factor. This hypothesis is based on the documented upregulation of TGF-β in scleroderma lesional skin, where it induces the activation of myofibroblasts [Nikitorowicz-Buniak et al. 2015] . However, it must be remembered that the literature reported some cases of SSc myopathy with inflammatory cells, predominantly CD8 + T lymphocytes with lower levels of CD4 + cells, few B cells and no complement capillary deposits [Bhansing et al. 2014] , as well as some cases with a majority of CD4 + T cells and B cells and complement deposits [Ranque et al. 2007 ]. Therefore, data related to the inflammatory infiltrate and the nature of immune response seem controversial and different possible patterns are envisaged.
In conclusion, our suggestion is to study and characterize each case of muscle involvement in SSc from the histological/immunohistological point of view, because of the heterogeneity of its manifestations. This advice is not simply speculative, but responds to the need to set up the suitable therapy for each case. In fact, high-dose steroids represent the first line treatment for all myositides except IBM [Dalakas, 2010] ; in SSc myopathic patients, highly susceptible to renal crisis, corticosteroids at the lowest effective dose should be restricted to subjects with histologically proven inflammation. Further studies should follow to determine whether histopathologic findings in SSc-related myopathy could influence clinical outcomes of specific targeted therapies.
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